ClinicalTrials.gg
CompletedNCT00908037PETITUpdated Oct 12, 2018Results posted

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

A Phase 2 interventional study of eltrombopag and Placebo in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 33 sites in 6 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2018-10-12.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: PurpuraReclassifiedWhy we changed it
Registry
Purpura — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's title name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Purpura.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
11th of 36
82 · median 40
Started
2009
with 2 others
Phase 2
15 of 36
2 open now
Registered
10th of 36
by date
Lead sponsor
9 of 36
GlaxoSmithKline

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 11th largest by enrollment, is one of 3 that started in 2009, is one of 15 in phase 2, and was the 10th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

Phase II, multi-center, 3 part, staggered cohort, open-label and double blind, randomized, placebo controlled study involving 3 age-determined cohorts (Cohort 1: between 12 and 17 years old; Cohort 2: between 6 and 11 years old; Cohort 3: between 1 and 5 years old). Daily dosing with eltrombopag will begin with 5 patients in the oldest age cohort in an open label fashion, and a review of safety, pharmacokinetic and platelet count data will be performed regularly. If no safety concerns are identified after 12 weeks, 18 additional patients will be randomised to placebo or eltrombopag (2:1 randomisation). After 7 weeks of randomized treatment, all patients will receive eltrombopag in an open label fashion. The total duration of treatment with eltrombopag will be 24 weeks. If at the time of the aforementioned 12 week review of the first 5 patients no safety issues are identified, dosing will begin in the next lower age cohort with an initial group of 5 patients. The same procedure will be followed in terms of safety review and subsequent enrolment and randomisation of the additional patients. Initiation of the younger age cohort will take place once data from the previous has been evaluated. Doses will be adjusted according to platelet counts and tolerability. The study will include a review of the safety data by a Data Safety Monitoring Board.

03

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Browse trials for

Keywords

  • idiopathic thrombocytopenic purpura
  • thrombocytopenia
  • pharmacodynamics
  • ITP
  • eltrombopag
  • pharmacokinetics
  • chronic ITP
  • pediatrics
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

This study's enrollment of 82 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects between 1 year and \<18 years of age at Day 1.
  • Written from subject's guardian and accompanying informed assent from subject (for children over 6 years old).
  • Confirmed diagnosis of chronic ITP, according to the American Society of Hematology / British Committee for Standards in Haematology (ASH/BCSH) guidelines [George, 1996; BCSH, 2003]. In addition, a peripheral blood smear or bone marrow examination should support the diagnosis of ITP with no evidence of other causes of thrombocytopenia.
  • Subjects who are or have relapsed after at least one prior ITP therapy or are not eligible, for a medical reason, for other treatments.
  • Day 1 (or within 48 hours prior) count \<30 Gi/L.
  • Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 2 weeks prior to Day 1 or have been clearly ineffective.
  • Subjects treated with concomitant ITP medication (e.g. or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to Day 1.
  • Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to Day 1 or have clearly been ineffective.
  • Subjects must have (PT/INR) and activated partial thromboplastin time (aPTT) within 80 to 120% of the normal range.
  • Subjects must have a complete blood count (CBC) not suggestive of another hematological disorder.
  • The following clinical chemistries for the subjects MUST NOT exceed the (ULN) reference range by more than 20%: creatinine, (ALT), aspartate aminotransferase (AST), total , and alkaline phosphatase. In addition, total albumin must not be below the lower limit of normal (LLN) by more than 10%.
  • For subjects of (after menarche): subject must not be sexually active or is practicing an acceptable method of (documented in chart). Female subjects (or female partners of male subjects) must use one of the following highly effective methods of contraception (i.e., Pearl Index \<1.0%) from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
  • Complete abstinence from intercourse;
  • Intrauterine device (IUD);
  • Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide);
  • Systemic contraceptives (combined or progesterone only).

Exclusion criteria

Exclusion Criteria:

  • Any abnormality, other than ITP, identified on the screening examination or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another primary diagnosis (e.g. thrombocytopenia is secondary to another disease).
  • Concurrent or past malignant disease, including myeloproliferative disorder.
  • Subjects who are not suitable for continuation of their current therapy for at least 7 additional additional weeks.
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding Day 1.
  • History of agglutination abnormality that prevents reliable measurement of platelet counts.
  • Diagnosis of secondary immune thrombocytopenia, including those with laboratory or clinical evidence of infection, anti-phospholipid antibody syndrome, chronic infection, virus infection, or any evidence of active hepatitis at the time of subject screening.
  • Subject with Evans syndrome ( thrombocytopenia and autoimmune hemolysis).
  • Subjects with known inherited thrombocytopenia (e.g. MYH-9 disorders)
  • Subjects treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for >3 consecutive days within 2 weeks of Day 1.
  • Subjects who have previously received eltrombopag or any other thrombopoietin receptor agonist.
  • For female subjects who have reached menarche status, an inability or unwillingness to provide a blood or urine specimen for pregnancy testing.
  • Female subjects who are pregnant or lactating.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    eltrombopag plus standard of care

    eltrombopag

    Drug: eltrombopag

  • Placebo comparator
    placebo plus standard of care

    placebo

    Drug: Placebo

Interventions

  • thrombopoietin receptor agonist

  • DrugPlacebo

    placebo for comparison

07

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2)

    Participants who achieved a platelet count \>=50 Gi/L at least once between Day 8 and Day 43 (first 6 weeks of Part 2) in the absense of rescue treatment were reported. A 95% confidence interval was calculated by the exact binomial method.

    Time frame: From Day 8 up to Day 43 of Part 2

Secondary outcomes

  1. Percentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2)

    Sustained platelet response between the treatment groups was assessed by determining the number of participants who achieved a platelet count \>=50 Gi/L during treatment with eltrombopag in \>= 60% of assessments between Day 15 and Day 43 in the absence of rescue treatment were reported here.

    Time frame: Between Day 15 and Day 43 of Part 2

  2. Weighted Mean Platelet Count

    The weighted mean platelet count is defined as the area under the platelet-time curve divided by the duration of the treatment (12 weeks). Based on the Analysis of Covariance (ANCOVA) model, the weighted mean platelet count is the sum of the Baseline count plus the age cohort plus the treatment. Baseline was defined as the platelet count taken on Day 1 or within 48 hours prior to the first dose of treatment.

    Time frame: Baseline and Day 43 of Part 2

  3. Percentage of Participants Achieving Platelet Counts >=50Gi/L at Any Time During the 24 Weeks of Eltrombopag Dosing During Part 1.

    The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment were reported.

    Time frame: From Day 1 of treatment up to Week 24 of Part 1

  4. Percentage of Participants Achieving Platelet Counts >=50 Gi/L at Any Time During the 31 Weeks of Eltrombopag Treatment During Part 2/ 3.

    The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment during Part 2/3 of the study were reported. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

    Time frame: Part 2/3 up to Study Week 31

  5. Population Pharmacokinetic (PK) Assessment for Eltrombopag for AUC(0-t) During Part 1, 2, and 2/3.

    The area under the concentration-time curve over the dosing interval (AUC0-t) data was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. From the final model, a single value of AUC(0-t) was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

    Time frame: From Day 1 of treatment up to Study Week 31

  6. Population Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax and Ct During Part 1, 2, and 2/3.

    The maximum observed concentration (Cmax) and the concentration at the end of the dosing interval (Ct) data were collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of Cmax and Ct were estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

    Time frame: From Day 1 of treatment up to Study Week 31

  7. Population Pharmacokinetic (PK) Assessments for Eltrombopag for Tmax During Part 1, 2, and 2/3

    The time to maximum concentration (tmax) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of tmax was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

    Time frame: From Day 1 of treatment up to Study Week 31

  8. Population Pharmacokinetic (PK) Assessments for Eltrombopag for CL/F During Part 1, 2, and 2/3

    The apparent plasma clearance following oral dosing of eltrombopag (CL/F) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of CL/F was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

    Time frame: From Day 1 of treatment up to Study Week 31

  9. Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 2

    The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Excludes periods from initiation of rescue medication until platelet count falls to below 50Gi/L, irrespective of platelet count

    Time frame: From Baseline through Week 7 of Part 2

  10. Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 24 Weeks of Eltrombopag Treatment in Part 2/ 3

    The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2/3. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

    Time frame: From Baseline up to Study Week 31

  11. Percentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1.

    The participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 1 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction is defined as reduction for 4 weeks or more. An attempted red or dis is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 1 Day 1 to the last dose of study medication + 1 day.

    Time frame: From Baseline up to Week 24+ 1 day of Part 1

  12. Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3

    Participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 2/3 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants randomized to placebo in Part 2, BL is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, BL is defined as Day 1 of Part 2. A sustained reduction is defined as reduction for 4 weeks or more. An attempted reduction or discontinuation is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 2/3 Day 1 to the last dose of study medication + 1 day.

    Time frame: From Baseline to the end of treatment up to Week 31 + 1 day of Part 2/3

  13. Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3

    Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy. For particpants randomized to placebo in Part 2, Baseline is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, Baseline is defined as Day 1 of Part 2. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

    Time frame: From Baseline to the end of treatment up to Week 31 + 1 day of Part2/3

  14. Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1

    The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

    Time frame: Baseline, Week 6, Week 12, and Week 24 of Part 1

  15. Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline and Week 6as Assessed Using the KIT Questionnaire During the Randomized Period, Part 2

    The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

    Time frame: Baseline and Week 6 of Part 2

  16. Kids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3

    The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1=never, 2=seldom, 3=sometimes, 4=often, 5=always and 9=not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

    Time frame: From Baseline to end of treatment up to Study Week 31

  17. Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2

    The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.

    Time frame: From Baseline through Week 7 of Part 2

  18. Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3

    The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.

    Time frame: From Baseline of Part 2/3 through Follow-up

  19. Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3

    Clinical chemistry parameters included: aspartate amino transferase (AST, reference range \[RR\]: 0-38 International Units per Liter \[IU/L\]), alkaline phosphatase (ALP: RR: 50 - 375 IU/L), total bilirubin (RR: 3.42 - 22.23 micromoles \[umol\]/L), albumin grams \[g/L\], alanine amino transferase (ALT, RR: 5-30 IU/L), prothrombin international normalized ratio (PT INR, RR-0.9 - 1.2), activated partial thromboplastin time (APTT, RR: 24.2 - 32.9 seconds), glucose (RR: 4.107- 6.55018 millimoles \[mmol\]/L), potassium (3 - 5 mmol/L), and sodium (135 - 143 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated clinical chemistry data outside of the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment

    Time frame: Post-Baseline from Week 1 through Follow-up up to Study Week 35

  20. Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3

    Hematology parameters included: erythrocytes (RR: 4.2 - 6.1 teragrams per liter \[TI/L\]), hemoglobin (RR: 125 - 165 g/L), hematocrit (RR: 0.36 - 0.46), platelets (RR: 170 - 430 gigagrams per liter \[GI/L\]), mean platelet volume (MPV, RR: 4 - 14 femotoliter \[fL\]), leukocytes (RR: 3.4 - 11.2 GI/L), total neutrophils (RR: 2.1 - 4.9 GI/L), lymphocytes (RR: 1.4 - 2.9 GI/L), monocytes (RR: 0.2 - 0.9 GI/L), eosinophils (RR: 0.2 - 0.7 GI/L), and basophils (RR: 0.02 - 0.12 GI/L). Baseline values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment

    Time frame: Post-Baseline from Week 1 through Follow-up up to Study Week 35

  21. Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3

    Renal parameters included: creatinine (RR: 44.2 - 88.4 umol/L), creatinine clearance derived (RR: 89.0 - 165.0 milliliter per minute \[ ml/min\]), protein/creatinine (RR: 0.113- 18.0992 microgram per millimoles \[mg/mmol\]), and urea (RR: 1.785- 8.925 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated renal parameters data outside the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-baseline assessment

    Time frame: Post-Baseline from Week 1 through Follow-up up to Study Week 35

  22. Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 1

    Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with a positive result at any time post Baseline were reported. A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.

    Time frame: From Baseline up to Study Week 24 of Part 1

  23. Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2

    Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The nmber of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.

    Time frame: From Baseline and post-Baseline up to Study Week 7 of Part 2

  24. Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3

    Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

    Time frame: From Baseline and post-Baseline up to Study Week 31 of Part 2/3

  25. Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3

    Vital sign assessments included systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements that were measured before any blood draw at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, at each Follow-up week (Week 1-4) and the maximum post- Baseline (BL) visit. BL is defined as the value obtained on Day 1of treatment. The maximum post-BL visit (MPB) included any scheduled and unscheduled post-BL assessment. Reference ranges (RR) for SBP (mmHg) (Lower limit of normal, normal, Upper limit of normal) for Cohort 1: \<85, 85-115, \>115; for Cohort 2: \<85, 85-120,\>120; and Cohort 3: \<95, 95-135, \>135. RR for DBP (mmHg) for Cohort 1: \<45, 45-70,\>70; for Cohort 2: \<50, 50-75, \>75; and Cohort 3: \<55, 55-85, \>85.

    Time frame: From Baseline through Study Week 35

  26. Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1

    Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.

    Time frame: From Baseline through Week 24

  27. Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2

    Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.

    Time frame: From Week 1 to Week 7 of Part 2

  28. Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3

    Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

    Time frame: From Week 1 to Follow-up Week 4 of Part 2/3 up to Study Week 35

  29. Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1

    Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline (MPB) visit included any scheduled and unscheduled post-Baseline assessment..

    Time frame: From Week 1 to Follow-up Week 4 of Part 1, up to Study Week 28

  30. Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2

    Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment.

    Time frame: From Week 1 to Week 7 of Part 2

  31. Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3

    Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

    Time frame: From Week 1to Follow-up Week 4 of Part 2/3, up to Study Week 35

  32. Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1

    Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.

    Time frame: Baseline and Week 24 of Part 1

  33. Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2

    Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 7 (W7). The Baseline value was the measurement taken at Day 1.

    Time frame: Baseline and Week 7 of Part 2

  34. Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3

    Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.

    Time frame: Baseline and Week 24 of Part 2/3 up to Study Week 31

  35. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

    Time frame: From Treatment + 1 day up to Week 24 of Part1

  36. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

    Time frame: From Treatment + 1 day up to Week 7 of Part 2

  37. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2/3

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

    Time frame: From Treatment + 1 day up to Week 31 of Part2/3

  38. Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with a change in visual acuity and worsening visual acuity due to cataracts since Baseline are presented for Part 1 Follow-up Visits at 3-months (FU3) and at 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".

    Time frame: Baseline, 3and 6-mo Follow-up of Part 1

  39. Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Number of participants with a change in visual acuity and change in visual acuity due to the worsening of cataracts since Baseline are presented for Part 2/3 Follow-up Visits at 3-months (FU3) and 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".

    Time frame: BL, 3 and 6mo Follow-up of Part 2/3

08

Results

Posted Oct 31, 2014

Participant flow

Pediatric participants (par.) meeting eligibility criteria were enrolled into 3 cohorts depending upon age. Cohort 1 enrolled participants who were between 12 and 17 years old, Cohort 2 enrolled participants who were between 6 and 11 years old, and Cohort 3 enrolled participants who were between 1 and 5 years old.

Part1 (24 Week Dose-Finding Period)
Participant flow — Part1 (24 Week Dose-Finding Period)
MilestonePart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3Part 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- EltrombopagPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open- Label Period) Cohort 3
Started555000000000
Completed555000000000
Not completed000000000000
Part 2 (7 Week Randomized Period)
Participant flow — Part 2 (7 Week Randomized Period)
MilestonePart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3Part 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- EltrombopagPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open- Label Period) Cohort 3
Started000816919510000
Completed00071391555000
Not completed000130405000
Withdrew: Protocol violation000010301000
Withdrew: Lost to follow-up000020004000
Withdrew: Withdrawal by parent/ guardian000100100000
Part 2/3(Eltrombopag Open-Label Period)
Participant flow — Part 2/3(Eltrombopag Open-Label Period)
MilestonePart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3Part 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- EltrombopagPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open- Label Period) Cohort 3
Started000000000242815
Completed000000000212412
Not completed000000000343
Withdrew: Lack of efficacy000000000001
Withdrew: Lost to follow-up000000000102
Withdrew: Withdrawal by parent/guardian000000000100
Withdrew: Adverse event000000000020
Withdrew: Physician decision000000000100
Withdrew: Randomized but did not receive treatment000000000020

Outcome measures

PrimaryPercentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2)

Participants who achieved a platelet count \>=50 Gi/L at least once between Day 8 and Day 43 (first 6 weeks of Part 2) in the absense of rescue treatment were reported. A 95% confidence interval was calculated by the exact binomial method.

Time frame:
From Day 8 up to Day 43 of Part 2
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2)
Percentage of ParticipantsPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2)062.533.363.280.060.0
SecondaryPercentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2)

Sustained platelet response between the treatment groups was assessed by determining the number of participants who achieved a platelet count \>=50 Gi/L during treatment with eltrombopag in \>= 60% of assessments between Day 15 and Day 43 in the absence of rescue treatment were reported here.

Time frame:
Between Day 15 and Day 43 of Part 2
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2)
Percentage of ParticipantsPart 2 (Randomized Period) -PlaceboPart 2 (Randomized Period) - Eltrombopag
Percentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2)035.6
SecondaryWeighted Mean Platelet Count

The weighted mean platelet count is defined as the area under the platelet-time curve divided by the duration of the treatment (12 weeks). Based on the Analysis of Covariance (ANCOVA) model, the weighted mean platelet count is the sum of the Baseline count plus the age cohort plus the treatment. Baseline was defined as the platelet count taken on Day 1 or within 48 hours prior to the first dose of treatment.

Time frame:
Baseline and Day 43 of Part 2
Reported as:
Mean · Gi/L
Weighted Mean Platelet Count
Gi/LPart 2 (Randomized Period) -PlaceboPart 2 (Randomized Period) - Eltrombopag
Baseline12.2 ± 8.5915.5 ± 8.03
Day 4330.5 ± 24.9868 ± 56.78
SecondaryPercentage of Participants Achieving Platelet Counts >=50Gi/L at Any Time During the 24 Weeks of Eltrombopag Dosing During Part 1.

The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment were reported.

Time frame:
From Day 1 of treatment up to Week 24 of Part 1
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Platelet Counts >=50Gi/L at Any Time During the 24 Weeks of Eltrombopag Dosing During Part 1.
Percentage of ParticipantsPart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
Percentage of Participants Achieving Platelet Counts >=50Gi/L at Any Time During the 24 Weeks of Eltrombopag Dosing During Part 1.808060
SecondaryPercentage of Participants Achieving Platelet Counts >=50 Gi/L at Any Time During the 31 Weeks of Eltrombopag Treatment During Part 2/ 3.

The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment during Part 2/3 of the study were reported. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Time frame:
Part 2/3 up to Study Week 31
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Platelet Counts >=50 Gi/L at Any Time During the 31 Weeks of Eltrombopag Treatment During Part 2/ 3.
Percentage of ParticipantsPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open-Label Period) Cohort 3
Percentage of Participants Achieving Platelet Counts >=50 Gi/L at Any Time During the 31 Weeks of Eltrombopag Treatment During Part 2/ 3.75.082.186.7
SecondaryPopulation Pharmacokinetic (PK) Assessment for Eltrombopag for AUC(0-t) During Part 1, 2, and 2/3.

The area under the concentration-time curve over the dosing interval (AUC0-t) data was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. From the final model, a single value of AUC(0-t) was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Time frame:
From Day 1 of treatment up to Study Week 31
Reported as:
Geometric mean · Microgram*hour per milliliter (ug*h/mL)
Population Pharmacokinetic (PK) Assessment for Eltrombopag for AUC(0-t) During Part 1, 2, and 2/3.
Microgram*hour per milliliter (ug*h/mL)Eltrombopag Cohort 1- 12-17 YearsEltrombopag Cohort 2 - 6-11 YearsEltrombopag Cohort 3 - 1-5 Years
Population Pharmacokinetic (PK) Assessment for Eltrombopag for AUC(0-t) During Part 1, 2, and 2/3.101 (87.1 to 117)132 (114 to 152)142 (117 to 173)
SecondaryPopulation Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax and Ct During Part 1, 2, and 2/3.

The maximum observed concentration (Cmax) and the concentration at the end of the dosing interval (Ct) data were collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of Cmax and Ct were estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Time frame:
From Day 1 of treatment up to Study Week 31
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax and Ct During Part 1, 2, and 2/3.
micrograms per milliliter (ug/mL)Eltrombopag Cohort 1- 12-17 YearsEltrombopag Cohort 2 - 6-11 YearsEltrombopag Cohort 3 - 1-5 Years
Cmax6.65 (5.87 to 7.53)9.19 (8.18 to 10.3)10.7 (9.24 to 12.5)
Ct2.42 (1.97 to 2.98)2.95 (2.41 to 3.60)2.91 (2.14 to 3.96)
SecondaryPopulation Pharmacokinetic (PK) Assessments for Eltrombopag for Tmax During Part 1, 2, and 2/3

The time to maximum concentration (tmax) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of tmax was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Time frame:
From Day 1 of treatment up to Study Week 31
Reported as:
Median · hour (hr)
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Tmax During Part 1, 2, and 2/3
hour (hr)Eltrombopag Cohort 1- 12-17 YearsEltrombopag Cohort 2 - 6-11 YearsEltrombopag Cohort 3 - 1-5 Years
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Tmax During Part 1, 2, and 2/34.0 (2.0 to 6.0)4.0 (2.0 to 6.0)2.0 (2.0 to 4.0)
SecondaryPopulation Pharmacokinetic (PK) Assessments for Eltrombopag for CL/F During Part 1, 2, and 2/3

The apparent plasma clearance following oral dosing of eltrombopag (CL/F) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of CL/F was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Time frame:
From Day 1 of treatment up to Study Week 31
Reported as:
Geometric mean · liter per hour (L/hr)
Population Pharmacokinetic (PK) Assessments for Eltrombopag for CL/F During Part 1, 2, and 2/3
liter per hour (L/hr)Eltrombopag Cohort 1- 12-17 YearsEltrombopag Cohort 2 - 6-11 YearsEltrombopag Cohort 3 - 1-5 Years
Population Pharmacokinetic (PK) Assessments for Eltrombopag for CL/F During Part 1, 2, and 2/30.50 (0.43 to 0.57)0.38 (0.33 to 0.44)0.25 (0.20 to 0.30)
SecondaryMaximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 2

The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Excludes periods from initiation of rescue medication until platelet count falls to below 50Gi/L, irrespective of platelet count

Time frame:
From Baseline through Week 7 of Part 2
Reported as:
Median · Weeks
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 2
WeeksPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 20.0 (0 to 0)1.0 (0 to 5)0.0 (0 to 2)2.0 (0 to 6)1.0 (0 to 2)1.0 (0 to 6)
SecondaryMaximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 24 Weeks of Eltrombopag Treatment in Part 2/ 3

The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2/3. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Time frame:
From Baseline up to Study Week 31
Reported as:
Median · Weeks
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 24 Weeks of Eltrombopag Treatment in Part 2/ 3
WeeksPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open-Label Period) Cohort 3
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 24 Weeks of Eltrombopag Treatment in Part 2/ 32.0 (0 to 23)8.0 (0 to 24)4.0 (0 to 24)
SecondaryPercentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1.

The participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 1 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction is defined as reduction for 4 weeks or more. An attempted red or dis is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 1 Day 1 to the last dose of study medication + 1 day.

Time frame:
From Baseline up to Week 24+ 1 day of Part 1
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1.
Percentage of ParticipantsPart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
Taking an ITP medication at BL020.00
Attempted red or dis0100.00
Permanent red or dis of all BL ITP mediation0100.00
Permanent red or dis at least 1 BL ITP medcation0100.00
SecondaryPercentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3

Participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 2/3 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants randomized to placebo in Part 2, BL is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, BL is defined as Day 1 of Part 2. A sustained reduction is defined as reduction for 4 weeks or more. An attempted reduction or discontinuation is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 2/3 Day 1 to the last dose of study medication + 1 day.

Time frame:
From Baseline to the end of treatment up to Week 31 + 1 day of Part 2/3
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3
Percentage of ParticipantsPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open-Label Period) Cohort 3
Taking an ITP medication at BL25.017.913.3
Attempted red or dis66.720.0100.0
Permanent (perm) dis of all BL ITP medication(med)16.720.050.0
Perm dis at least 1 BL ITP med33.320.050.0
Perm dis all BL ITP med taken prior to Part 2/3040.00
SecondaryNumber of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3

Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy. For particpants randomized to placebo in Part 2, Baseline is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, Baseline is defined as Day 1 of Part 2. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Time frame:
From Baseline to the end of treatment up to Week 31 + 1 day of Part2/3
Reported as:
Number · Participants
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3
ParticipantsPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open-Label Period) Cohort 3
New ITP Medication844
Increase concomitant ITP medication from Baseline100
Platelet transfusion000
Splenectomy000
SecondaryKids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1

The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

Time frame:
Baseline, Week 6, Week 12, and Week 24 of Part 1
Reported as:
Mean · Score on scale
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1
Score on scalePart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
Baseline, n=5, 5, 573.18 ± 15.74353.95 ± 16.53474.80 ± 17.199
Week 6, n=4, 5, 582.84 ± 9.13161.57 ± 13.66471.54 ± 14.798
Week 12, n=4, 4, 484.14 ± 11.71266.43 ± 12.34965.58 ± 17.887
Week 24, n= 3, 4, 376.38 ± 20.22882.50 ± 15.99578.87 ± 12.056
SecondaryKids' ITP Tool (KIT) Questionnaire Total Score at Baseline and Week 6as Assessed Using the KIT Questionnaire During the Randomized Period, Part 2

The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

Time frame:
Baseline and Week 6 of Part 2
Reported as:
Mean · Score on scale
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline and Week 6as Assessed Using the KIT Questionnaire During the Randomized Period, Part 2
Score on scalePart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
Baseline, n=6, 11, 9, 10, 2, 883.94 ± 8.67476.84 ± 15.04971.05 ± 19.58166.36 ± 17.32182.61 ± 7.68678.23 ± 9.575
Week 6, n= 8,11,7,13, 5, 979.46 ± 10.97179.46 ± 13.89974.65 ± 20.96880.16 ± 13.77688.01 ± 3.33380.85 ± 15.082
SecondaryKids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3

The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1=never, 2=seldom, 3=sometimes, 4=often, 5=always and 9=not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

Time frame:
From Baseline to end of treatment up to Study Week 31
Reported as:
Mean · Score on scale
Kids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3
Score on scalePart 2/3 (Eltrombopag Period) Cohort 1Part 2/3 (Eltrombopag Period) Cohort 2Part 2/3 (Eltrombopag Period) Cohort 3
Baseline, n=17, 18, 1079.34 ± 13.31570.59 ± 16.23779.10 ± 9.016
Week 6, n=11, 13, 979.46 ± 13.89980.16 ± 13.77680.85 ± 15.082
Week 12, n=9, 7, 284.25 ± 7.53176.48 ± 19.94888.10 ± 11.166
Week 24, n=17, 11, 882.16 ± 16.92683.93 ± 13.32777.93 ± 22.971
SecondaryNumber of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2

The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.

Time frame:
From Baseline through Week 7 of Part 2
Reported as:
Number · Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2
ParticipantsPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
Baseline, Grades 1-4, n=8, 16, 9, 19, 5, 1061671158
Baseline, Grades 0-1, n=8, 16, 9, 19, 5, 1061361746
Baseline, Grades 2-4, n=8, 16, 9, 19, 5, 10233214
Week 1, Grades 1-4, n=8, 16, 9, 17, 5, 10796737
Week 1, Grades 0-1, n=8, 16, 9, 17, 5, 1031461755
Week 1, Grades 2-4, n=8, 16, 9, 17, 5, 10523005
Week 2, Grades 1-4, n=8, 16, 9, 17, 5, 107116625
Week 2, Grades 0-1, n=8, 16, 9, 17, 5, 1051371637
Week 2, Grades 2-4, n=8, 16, 9, 17, 5, 10332123
Week 3, Grades 1-4, n=8, 16, 9, 16, 5, 96107625
Week 3, Grades 0-1, n=8, 16, 9, 16, 5, 951471437
Week 3, Grades 2-4, n=8, 16, 9, 16, 5, 9322222
Week 4, Grades 1-4, n=8, 16, 9, 17, 5, 9677726
Week 4, Grades 0-1, n=8, 16, 9, 17, 5, 961681737
Week 4, Grades 2-4, n=8, 16, 9, 17, 5, 9201022
Week 5, Grades 1-4, n=8, 16, 9, 16, 5, 9687345
Week 5, Grades 0-1, n=8, 16, 9, 16, 5, 941481648
Week 5, Grades 2-4, n=8, 16, 9, 16, 5, 9421011
Week 6, Grades 1-4, n=8, 16, 9, 17, 5, 9527444
Week 6, Grades 0-1, n=8, 16, 9, 17, 5, 971671649
Week 6, Grades 2-4, n=8, 16, 9, 17, 5, 9102110
Week 7, Grades 1-4, n=8, 16, 9, 17, 5, 9757544
Week 7, Grades 0-1, n=8, 16, 9, 17, 5, 941581637
Week 7, Grades 2-4, n=8, 16, 9, 17, 5, 9411122
SecondaryNumber of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3

The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.

Time frame:
From Baseline of Part 2/3 through Follow-up
Reported as:
Number · Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3
ParticipantsPart 2/ 3 (Eltrombopag Period) Cohort 1Part 2/3 (Eltrombopag Period) Cohort 2Part 2/3 (Eltrombopag Period) Cohort 3
Baseline, Grades 1-4, n=24, 28, 15231812
Baseline, Grades 0-1, n=24, 28, 1517259
Baseline, Grades 2-4, n=24, 28, 15736
Week 1, Grades 1-4, n=24, 26, 1514139
Week 1, Grades 0-1, n=24, 26, 1520249
Week 1, Grades 2-4, n=24, 26, 15426
Week 2, Grades 1-4, n=24, 26, 1415128
Week 2, Grades 0-1, n=24, 26, 14212310
Week 2, Grades 2-4, n=24, 26, 14334
Week 3, Grades 1-4, n=24, 25, 141396
Week 3, Grades 0-1, n=24, 25, 14212312
Week 3, Grades 2-4, n=24, 25, 14322
Week 4, Grades 1-4, n=24, 26, 1310118
Week 4, Grades 0-1, n=24, 26, 13242610
Week 4, Grades 2-4, n=24, 26, 13003
Week 5, Grades 1-4, n=24, 24, 131149
Week 5, Grades 0-1, n=24, 24, 13212412
Week 5, Grades 2-4, n=24, 24, 13301
Week 6, Grades 1-4, n=23, 24, 12664
Week 6, Grades 0-1, n=23, 24, 12232212
Week 6, Grades 2-4, n=23, 24, 12020
Week 7, Grades 1-4, n=22, 25, 14874
Week 7, Grades 0-1, n=22, 25, 14202412
Week 7, Grades 2-4, n=22, 25, 14212
Week 8, Grades 1-4, n=19, 21, 111065
Week 8, Grades 0-1, n=19, 21, 1119199
Week 8, Grades 2-4, n=19, 21, 11022
Week 9, Grades 1-4, n=17, 16, 12856
Week 9, Grades 0-1, n=17, 16, 12131610
Week 9, Grades 2-4, n=17, 16, 12402
Week 10, Grades 1-4, n=16, 14, 11557
Week 10, Grades 0-1, n=16, 14, 11161211
Week 10, Grades 2-4, n=16, 14, 11020
Week 11, Grades 1-4, n=16, 15, 121557
Week 11, Grades 0-1, n=16, 15, 12161310
Week 11, Grades 2-4, n=16, 15, 12022
Week 12, Grades 1-4, n=19, 16, 9674
Week 12, Grades 0-1, n=19, 16, 918147
Week 12, Grades 2-4, n=19, 16, 9122
Week 13, Grades 1-4, n=12, 14, 10656
Week 13, Grades 0-1, n=12, 14, 10121310
Week 13, Grades 2-4, n=12, 14, 10010
Week 14, Grades 1-4, n=15, 11, 17323
Week 14, Grades 0-1, n=15, 11, 1715115
Week 14, Grades 2-4, n=15, 11, 17002
Week 15, Grades 1-4, n=12, 14, 6633
Week 15, Grades 0-1, n=12, 14, 610145
Week 15, Grades 2-4, n=12, 14, 6201
Week 16, Grades 1-4, n=17, 15, 9784
Week 16, Grades 0-1, n=17, 15, 917149
Week 16, Grades 2-4, n=17, 15, 9010
Week 17, Grades 1-4, n=13, 11, 5534
Week 17, Grades 0-1, n=13, 11, 513115
Week 17, Grades 2-4, n=13, 11, 5000
Week 18, Grades 1-4, n=16, 12 ,4323
Week 18, Grades 0-1, n=16, 12 ,416114
Week 18, Grades 2-4, n=16, 12 ,4010
Week 19, Grades 1-4, n=14, 15, 7341
Week 19, Grades 0-1, n=14, 15, 714147
Week 19, Grades 2-4, n=14, 15, 7010
Week 20, Grades 1-4, n=13, 13, 8232
Week 20, Grades 0-1, n=13, 13, 813136
Week 20, Grades 2-4, n=13, 13, 8002
Week 21, Grades 1-4, n=4, 10, 3100
Week 21, Grades 0-1, n=4, 10, 34103
Week 21, Grades 2-4, n=4, 10, 3000
Week 22, Grades 1-4, n=12,7, 5222
Week 22 Grades 0-1, n=12,7, 51265
Week 22 Grades 2-4, n=12,7, 5010
Week 23, Grades 1-4, n=8, 7,6112
Week 23, Grades 0-1, n=8, 7,6876
Week 23, Grades 2-4, n=8, 7,6000
Week 24, Grades 1-4, n=23, 24, 13554
Week 24, Grades 0-1, n=23, 14, 13212412
Week 24, Grades 2-4, n=23, 14, 13201
Follow Up Week 1, Grades 1-4, n=8, 5, 3513
Follow Up Week 1, Grades 0-1, n=8, 5, 3842
Follow Up Week 1, Grades 2-4, n=8, 5, 3011
Follow Up Week 2, Grades 1-4, n=7, 7, 7262
Follow Up Week 2, Grades 0-1, n=7, 7, 7766
Follow Up Week 2, Grades 2-4, n=7, 7, 7011
Follow Up Week 3, Grades 1-4, n=5, 5, 5124
Follow Up Week 3, Grades 0-1, n=5, 5, 5554
Follow Up Week 3, Grades 2-4, n=5, 5, 5001
Follow Up Week 4, Grades 1-4, n=9, 14, 8543
Follow Up Week 4, Grades 0-1, n=9, 14, 88137
Follow Up Week 4, Grades 2-4, n=9, 14, 8111
Any Follow Up Visit, Grades 1, n=15, 18, 107105
Any Follow Up Visit, Grades 0-1, n=15, 18, 1015189
Any Follow Up Visit, Grades 2-4, n=15, 18, 10133
SecondaryNumber of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3

Clinical chemistry parameters included: aspartate amino transferase (AST, reference range \[RR\]: 0-38 International Units per Liter \[IU/L\]), alkaline phosphatase (ALP: RR: 50 - 375 IU/L), total bilirubin (RR: 3.42 - 22.23 micromoles \[umol\]/L), albumin grams \[g/L\], alanine amino transferase (ALT, RR: 5-30 IU/L), prothrombin international normalized ratio (PT INR, RR-0.9 - 1.2), activated partial thromboplastin time (APTT, RR: 24.2 - 32.9 seconds), glucose (RR: 4.107- 6.55018 millimoles \[mmol\]/L), potassium (3 - 5 mmol/L), and sodium (135 - 143 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated clinical chemistry data outside of the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment

Time frame:
Post-Baseline from Week 1 through Follow-up up to Study Week 35
Reported as:
Number · Participants
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3
ParticipantsPart 1 (Dose-Finding Period)Part 2 (Randomized Period) -PlaceboPart 2 (Randomized Period) - EltrombopagPart 2/3 (Eltrombopag Open-Label Period)
AST high, n=15, 21, 44, 6554717
AST low, n=15, 21, 44, 651137
ALT, high, n= 15, 21, 44, 6523314
ALT, low, n= 15, 21, 44, 6523411
Total Bilirubin, high, n=15, 21, 44, 655229
Total Bilirubin, low, n=15, 21, 44, 65601631
Direct Bilirubin, high, n=10, 16, 34, 550113
Direct Bilirubin, low, n=10, 16, 34, 551068
Albumin, high, n=15, 21, 24, 653329
Albumin, low, n=15, 21, 24, 6513511
ALP, high, n=15, 21, 24, 6541613
ALP, low, n=15, 21, 24, 6522411
PT INR, high, n=15, 20, 42, 6421412
PT INR, low, n=15, 20, 42, 640001
PT, high, n=13, 20, 36, 6155824
PT, low, n=13, 20, 36, 610103
PTT, high, n=15, 21, 41, 6342111
PTT, low, n=15, 21, 41, 630119
Glucose, high, n=15, 21, 44, 6555727
Glucose, low, n=15, 21, 44, 65761629
Potassium, high, n=15, 21, 44, 657039
Potassium, low, n=15, 21, 44, 65,34814
Sodium, high, n=15, 21, 44, 652126
Sodium, low, n=15, 21, 44, 652149
SecondaryNumber of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3

Hematology parameters included: erythrocytes (RR: 4.2 - 6.1 teragrams per liter \[TI/L\]), hemoglobin (RR: 125 - 165 g/L), hematocrit (RR: 0.36 - 0.46), platelets (RR: 170 - 430 gigagrams per liter \[GI/L\]), mean platelet volume (MPV, RR: 4 - 14 femotoliter \[fL\]), leukocytes (RR: 3.4 - 11.2 GI/L), total neutrophils (RR: 2.1 - 4.9 GI/L), lymphocytes (RR: 1.4 - 2.9 GI/L), monocytes (RR: 0.2 - 0.9 GI/L), eosinophils (RR: 0.2 - 0.7 GI/L), and basophils (RR: 0.02 - 0.12 GI/L). Baseline values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment

Time frame:
Post-Baseline from Week 1 through Follow-up up to Study Week 35
Reported as:
Number · Participants
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3
ParticipantsPart 1 (Dose-Finding Period)Part 2 (Randomized Period) -PlaceboPart 2 (Randomized Period) - EltrombopagPart 2/ 3 (Eltrombopag Open-Label Period)
Erythrocytes high, n=15, 21, 44, 6550715
Erythrocytes low, n=15, 21, 44, 65281324
Hemoglobin, high, n= 15, 21, 44, 652228
Hemoglobin low, n= 15, 21, 44, 651051532
Hematocrit, high, n=15, 21, 44, 651005
Hematocrit, low, n=15, 21, 44, 6510112239
Platelets, high, n=15, 21, 44, 6590614
Platelets, low, n=15, 21, 44, 6515214465
Leukocytes, high, n=15, 21, 44, 6565827
Leukocytes, low, n=15, 21, 44, 65451019
Neutrophils, high, n=15, 21, 44, 65751133
Neutrophils, low, n=15, 21, 44, 65341021
Lymphocytes, high, n=15, 21, 44, 6513511
Lymphocytes, low, n=15, 21, 44, 65561025
Monocytes, high, n=15, 21, 44, 6533715
Monocytes, low, n=15, 21, 44, 65471023
Eosinophils, high, n=15, 21, 44, 65531124
Eosinophils, low, n=15, 21, 44, 654259
Basophils, high, n=15, 21, 44, 65651020
Basophils, low, n=15, 21, 44, 652011
Mean Platelet Volume, high, n=12, 17, 40, 5910102347
Mean Platelet Volume, low, n=12, 17, 40, 59461016
SecondaryNumber of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3

Renal parameters included: creatinine (RR: 44.2 - 88.4 umol/L), creatinine clearance derived (RR: 89.0 - 165.0 milliliter per minute \[ ml/min\]), protein/creatinine (RR: 0.113- 18.0992 microgram per millimoles \[mg/mmol\]), and urea (RR: 1.785- 8.925 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated renal parameters data outside the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-baseline assessment

Time frame:
Post-Baseline from Week 1 through Follow-up up to Study Week 35
Reported as:
Number · Participants
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3
ParticipantsPart 1 (Dose-Finding Period)Part 2 (Randomized Period) -PlaceboPart 2 (Randomized Period) - EltrombopagPart 2/ 3 (Eltrombopag Open-Label Period)
Creatinine, high, n=15, 21, 44, 6513613
Creatinine, low, n=15, 21, 44, 6554412
Creatinine Clearance Derived, high, n=15, 21,44,6511172846
Creatinine Clearance Derived, low, n=15, 21,44,650234
Protein/Creatinine, high, n=12, 19, 38, 5812418
Protein/Creatinine, low, n=12, 19, 38, 581000
Urea, high, n=15, 21, 44, 651225
Urea, low, n=15, 21, 44, 6551911
SecondaryNumber of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 1

Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with a positive result at any time post Baseline were reported. A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.

Time frame:
From Baseline up to Study Week 24 of Part 1
Reported as:
Number · Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 1
ParticipantsPart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
Epithelial Renal Cell Casts002
RBC Casts000
WBC Casts000
SecondaryNumber of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2

Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The nmber of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts.

Time frame:
From Baseline and post-Baseline up to Study Week 7 of Part 2
Reported as:
Number · Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2
ParticipantsPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
Pre-trt Epithelial Renal Tubular Cell Casts020000
Pre-trt RBC Casts010000
Pre-trt WBC Casts000000
Post-BL Epithelial Renal Tubular Cell Casts130010
Post-BL RBC Casts000000
Post-BL WBC Casts000001
SecondaryNumber of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3

Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Time frame:
From Baseline and post-Baseline up to Study Week 31 of Part 2/3
Reported as:
Number · Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3
ParticipantsPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open- Label Period) Cohort 3
Pre-trt Epithelial Renal Tubular Cell Casts301
Pre-trt RBC Casts100
Pre-trt WBC Casts000
Post-BL Epithelial Renal Tubular Cell Casts321
Post-BL RBC Casts001
Post-BL WBC Casts101
SecondaryNumber of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3

Vital sign assessments included systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements that were measured before any blood draw at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, at each Follow-up week (Week 1-4) and the maximum post- Baseline (BL) visit. BL is defined as the value obtained on Day 1of treatment. The maximum post-BL visit (MPB) included any scheduled and unscheduled post-BL assessment. Reference ranges (RR) for SBP (mmHg) (Lower limit of normal, normal, Upper limit of normal) for Cohort 1: \<85, 85-115, \>115; for Cohort 2: \<85, 85-120,\>120; and Cohort 3: \<95, 95-135, \>135. RR for DBP (mmHg) for Cohort 1: \<45, 45-70,\>70; for Cohort 2: \<50, 50-75, \>75; and Cohort 3: \<55, 55-85, \>85.

Time frame:
From Baseline through Study Week 35
Reported as:
Number · Participants
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3
ParticipantsPart 1 Eltrombopag Dose-Finding PeriodPart 2 Randomized Period - PlaceboPart 2 Randomized Period - EltrombopagPart 2/ 3 (Eltrombopag Open-Label Period)
Screening, DBP, high, n=15 ,20 ,41 ,401433
Screening, DBP, low, n=15, 20, 41, 400265
Day 1, DBP, high, n=14, 18, 38, 592437
Day 1, DBP, low, n=14, 18, 38, 591134
Week 1, DBP, high, n=14, 19, 42, 631345
Week 1, DBP, low, n=14, 19, 42, 631145
Week 2, DBP, high, n=15, 20, 42, 613223
Week 2, DBP, low, n=15, 20, 42, 612345
Week 3, DBP, high,n=15, 21, 41, 601336
Week 3, DBP, low,n=15, 21, 41, 602355
Week 4, DBP,high, n=15, 21, 42, 620336
Week 4, DBP,low, n=15, 21, 42, 624435
Week 5, DBP, high, n=15, 19, 40, 591248
Week 5, DBP, low, n=15, 19, 40, 591155
Week 6, DBP, high, n=14, 21, 42, 581235
Week 6, DBP, low, n=14, 21, 42, 580034
Week 7, DBP, high, n=15, 21, 42, 581467
Week 7, DBP, low, n=15, 21, 42, 580124
Week 8, DBP,high,n=15, 0, 0, 490NANA4
Week 8, DBP,low,n=15, 0, 0, 491NANA6
Week 9, DBP, high, n=15, 0, 0, 452NANA4
Week 9, DBP, low, n=15, 0, 0, 451NANA6
Week 10, DBP, high, n=15, 0, 0, 400NANA6
Week 10, DBP, low, n=15, 0, 0, 400NANA3
Week 11, DBP, high, n=13, 0, 0, 410NANA4
Week 11, DBP, low, n=13, 0, 0, 412NANA3
Week 12, DBP, high, n=13, 0, 0, 420NANA5
Week 12, DBP, low, n=13, 0, 0, 423NANA3
Week 13, DBP, high, n=12, 0, 0, 320NANA0
Week 13, DBP, low, n=12, 0, 0, 320NANA5
Week 14, DBP, high, n=9, 0, 0, 320NANA3
Week 14, DBP, low, n=9, 0, 0, 321NANA3
Week 15, DBP, high, n=11, 0, 0, 311NANA3
Week 15, DBP, low, n=11, 0, 0, 312NANA0
Week 16, DBP,high,n=12, 0, 0, 390NANA2
Week 16, DBP,low,n=12, 0, 0, 390NANA3
Week 17, DBP,high,n=5, 0, 0, 290NANA2
Week 17, DBP,low,n=5, 0, 0, 291NANA1
Week 18, DBP,high,n=9, 0, 0, 320NANA3
Week 18, DBP,low,n=9, 0, 0, 321NANA1
Week 19, DBP,high,n=5, 0, 0, 340NANA1
Week 19, DBP,low,n=5, 0, 0, 340NANA2
Week 20, DBP,high,n=13, 0, 0, 330NANA0
Week 20, DBP,low,n=13, 0, 0, 330NANA1
Week 21, DBP,high,n=10, 0, 0, 171NANA1
Week 21, DBP,low,n=10, 0, 0, 171NANA1
Week 22, DBP,high,n=11, 0, 0, 231NANA1
Week 22, DBP,low,n=11, 0, 0, 231NANA0
Week 23, DBP,high,n=11, 0, 0, 210NANA1
Week 23, DBP,low,n=11, 0, 0, 212NANA2
Week 24 DBP,high,n=15, 0, 0, 580NANA5
Week 24, DBP,low,n=15, 0, 0, 583NANA3
FU Week 1, DBP,high,n=5, 0, 0, 131NANA2
FU Week 1, DBP,low,n=5, 0, 0, 131NANA1
FU Week 2, DBP,high,n=5, 0, 0, 210NANA2
FU Week 2, DBP,low,n=5, 0, 0, 210NANA1
FU Week 3, DBP,high,n=5, 0, 0, 140NANA2
FU Week 3, DBP,low,n=5, 0, 0, 140NANA0
FU Week 4, DBP,high,n=3, 0, 0, 310NANA7
FU Week 4, DBP,low,n=3, 0, 0, 311NANA5
Screening, SBP, high, n=15, 20, 41, 40441010
Screening, SBP, low, n=15, 20, 41, 403032
Day 1, SBP,high,n=14, 18, 38, 5945914
Day 1, SBP,low,n=14, 18, 38, 590144
Week 1, SBP,high,n=14, 19, 42, 63361418
Week 1, SBP,low,n=14, 19, 42, 632048
Week 2, SBP,high,n=15, 20, 43, 6247715
Week 2, SBP,low,n=15, 20, 43, 621256
Week 3, SBP,high,n=15, 21, 41, 60341217
Week 3, SBP,low,n=15, 21, 41, 601223
Week 4, SBP,high,n=15, 21, 42, 62461016
Week 4, SBP,low,n=15, 21, 42, 624132
Week 5, SBP,high,n=15, 19, 40, 59551317
Week 5, SBP, low, n=15, 19, 40, 592133
Week 6, SBP,high,n=14, 21, 42, 58481116
Week 6, SBP,low,n=14, 21, 42, 582135
Week 7, SBP,high,n=15, 21, 42, 5855913
Week 7, SBP,low,n=15, 21, 42, 581025
Week 8, SBP,high,n=15, 0, 0, 493NANA16
Week 8, SBP,low,n=15, 0, 0, 494NANA4
Week 9, SBP,high,n=15, 0, 0, 454NANA15
Week 9, SBP,low,n=15, 0, 0, 453NANA2
Week 10, SBP,high,n=15, 0, 0, 402NANA10
Week 10, SBP,low,n=15, 0, 0, 402NANA3
Week 11, SBP,high,n=13, 0, 0, 414NANA9
Week 11, SBP,low,n=13, 0, 0, 412NANA2
Week 12, SBP,high,n=13, 0, 0, 423NANA10
Week 12, SBP,low,n=13, 0, 0, 423NANA3
Week 13, SBP,high,n=12, 0, 0, 323NANA8
Week 13, SBP,low,n=12, 0, 0, 322NANA3
Week 14, SBP,high,n=9, 0, 0, 324NANA10
Week 14, SBP,low,n=9, 0, 0, 320NANA3
Week 15, SBP,high,n=11, 0, 0, 313NANA9
Week 15, SBP,low,n=11, 0, 0, 312NANA1
Week 16 SBP,high,n=12, 0, 0, 395NANA14
Week 16, SBP,low,n=12, 0, 0, 391NANA1
Week 17, SBP,high,n=5, 0, 0, 291NANA9
Week 17, SBP,low,n=5, 0, 0, 291NANA0
Week 18, SBP,high,n=9, 0, 0, 322NANA10
Week 18, SBP,low,n=9, 0, 0, 320NANA1
Week 19, SBP,high,n=5, 0, 0, 342NANA9
Week 19, SBP,low,n=5, 0, 0, 340NANA2
Week 20, SBP,high,n=13, 0, 0, 336NANA10
Week 20, SBP,low,n=13, 0, 0, 332NANA1
Week 21, SBP,high,n=10, 0, 0, 172NANA0
Week 21, SBP,low,n=10, 0, 0, 173NANA0
Week 22, SBP,high,n=11, 0, 0, 232NANA8
Week 22, SBP,low,n=11, 0, 0, 233NANA0
Week 23, SBP,high,n=11, 0, 0, 212NANA6
Week 23, SBP,low,n=11, 0, 0, 212NANA1
Week 24, SBP,high,n=15, 0, 0, 584NANA19
Week 24, SBP, low, n=15, 0, 0, 582NANA2
FU Week 1, SBP, high,n=5, 0, 0, 130NANA4
FU Week 1, SBP, low,n=5, 0, 0, 132NANA0
FU Week 2, SBP, high,n=5, 0, 0, 212NANA3
FU Week 2, SBP, low,n=5, 0, 0, 210NANA3
FU Week 3, SBP, high,n=5, 0, 0, 141NANA4
FU Week 3, SBP, low,n=5, 0, 0, 140NANA0
FU Week 4, SBP, high,n=3, 0, 0, 311NANA10
FU Week 4, SBP,low,n=3, 0, 0, 311NANA3
SecondaryMean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1

Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.

Time frame:
From Baseline through Week 24
Reported as:
Mean · Breaths per min
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1
Breaths per minPart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
BL, n=4, 5, 420.0 ± 0.0021.4 ± 4.1025.5 ± 4.43
Week 1, n=4,5,421.5 ± 4.4322.0 ± 6.0026.5 ± 6.40
Week 2, n=5,5,420.6 ± 3.4419.4 ± 4.9824.0 ± 5.42
Week 3, n=5,5,522.0 ± 5.6617.0 ± 5.1023.6 ± 6.07
Week 4, n=5,5,518.8 ± 1.7917.2 ± 4.8225.4 ± 5.98
Week 5, n=5,5,420.4 ± 2.1920.2 ± 6.8724.3 ± 5.56
Week 6, n=5,5,418.4 ± 2.6120.2 ± 5.0224.5 ± 2.52
Week 7, n=5,5,519.2 ± 1.1023.4 ± 9.1524.4 ± 6.69
Week 8, n=5,5,519.8 ± 3.0320.4 ± 3.0523.8 ± 4.82
Week 9, n=5,4,519.2 ± 2.2822.5 ± 3.7922.0 ± 2.00
Week 10, n=5,5,519.6 ± 2.6118.0 ± 4.0022.4 ± 1.67
Week 11, n=5,3,419.6 ± 1.6720.3 ± 3.2125.0 ± 5.03
Week 12, n=4,3,419.5 ± 1.0020.0 ± 0.0027.6 ± 11.52
Week 13, n=4,4,419.5 ± 1.0021.0 ± 2.1623.0 ± 3.46
Week 14, n=3,3,318.7 ± 1.1522.7 ± 1.1527.3 ± 7.57
Week 15, n=3,3,318.0 ± 2.0021.3 ± 1.1524.0 ± 2.00
Week 16, n=5,3,418.8 ± 3.3520.0 ± 4.0030.8 ± 16.88
Week 17, n=2,0,318.0 ± 0.00NA ± NA24.0 ± 4.00
Week 18, n=3,3,419.3 ± 1.1521.3 ± 3.0629.0 ± 13.22
Week 19, n=3,0,219.3 ± 1.15NA ± NA28.0 ± 11.31
Week 20, n=5,4,419.6 ± 1.6721.5 ± 3.0023.5 ± 3.42
Week 21, n=3,2,519.3 ± 1.1519.00 ± 1.4123.6 ± 3.51
Week 22, n=3,4,319.3 ± 2.3121.0 ± 2.0027.3 ± 7.57
Week 23, n=4,2,420.0 ± 1.6320.0 ± 0.0021.5 ± 1.91
Week 24, n=5,5,419.6 ± 0.8923.0 ± 3.1624.8 ± 7.09
FU Week 1, n=1,1,320.0 ± NA20.0 ± NA22.0 ± 2.00
FU Week 2, n=3,2,019.3 ± 1.1526.5 ± 9.19NA ± NA
FU Week 3, n=2,1,221.0 ± 4.2428.0 ± NA24.5 ± 4.95
FU Week 4, n=1,0,118.0 ± NANA ± NA24.0 ± NA
MPB, n=5, 5, 524.4 ± 4.5629.8 ± 6.0232.2 ± 13.90
SecondaryMean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2

Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline value included any scheduled and unscheduled post-Baseline assessment.

Time frame:
From Week 1 to Week 7 of Part 2
Reported as:
Mean · Breaths per min
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2
Breaths per minPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
BL, n= 5, 14, 9, 12, 3, 1019.6 ± 1.6718.4 ± 2.3819.4 ± 3.1321.5 ± 10.0318.7 ± 1.1521.4 ± 2.12
Week 1, n=7, 16 ,9, 17, 2, 1019.0 ± 1.0018.8 ± 1.7619.9 ± 2.2620.7 ± 4.4819.0 ± 1.4128.2 ± 9.54
Week 2, n=6, 15, 9, 16, 4, 1019.3 ± 2.7318.9 ± 2.7019.8 ± 2.3323.0 ± 8.0121.5 ± 5.0027.1 ± 11.70
Week 3, n=8, 16, 9, 16, 4, 918.8 ± 1.8318.9 ± 1.9320.1 ± 2.7622.3 ± 4.7821.0 ± 2.5825.8 ± 7.17
Week 4, n=7, 16, 8, 14, 4, 1019.4 ± 2.5118.6 ± 2.8019.8 ± 2.4921.4 ± 4.2921.5 ± 1.0025.4 ± 7.18
Week 5, n=8, 16, 8, 15, 3, 819.3 ± 1.0418.5 ± 2.1020.5 ± 2.9819.7 ± 2.7420.0 ± 2.0029.0 ± 14.77
Week 6, n=8, 16, 9, 15, 4, 920.3 ± 2.2519.4 ± 2.1620.6 ± 2.1920.6 ± 4.1221.0 ± 1.1524.4 ± 6.69
Week 7, n=7, 16, 9, 17, 4, 820.9 ± 2.2718.4 ± 1.5020.9 ± 3.3320.7 ± 7.8718.5 ± 1.9123.5 ± 6.12
MPB, n=8, 16, 9, 17, 4, 1121.5 ± 2.3321.3 ± 21.822.7 ± 2.4526.6 ± 7.8723.5 ± 3.4230.0 ± 13.39
SecondaryMean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3

Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Time frame:
From Week 1 to Follow-up Week 4 of Part 2/3 up to Study Week 35
Reported as:
Mean · Breaths per minute
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3
Breaths per minutePart 2/3 (Eltrombopag Period) Cohort 1Part 2/3 (Eltrombopag Period) Cohort 2Part 2/3 (Eltrombopag Period) Cohort 3
Screening, n=16, 14, 1018.5 ± 1.7521.2 ± 6.5721.5 ± 2.56
Day 1 , n=21, 21, 1519.2 ± 2.572.12 ± 7.7421.7 ± 4.76
Week 1, n=24, 25, 1419.1 ± 1.7420.4 ± 3.9325.1 ± 7.63
Week 2, n=22, 24, 1319.4 ± 2.5621.8 ± 6.8525.2 ± 10.83
Week 3, n=24, 23, 1218.8 ± 1.7321.2 ± 4.4024.0 ± 6.09
Week 4, n=23, 23, 1319.0 ± 2.5920.9 ± 3.8224.3 ± 6.37
Week 5, n=23, 23, 1118.9 ± 2.1319.8 ± 3.1926.9 ± 12.91
Week 6, n=23, 22, 1119.3 ± 2.3020.6 ± 4.1123.3 ± 4.92
Week 7, n=22, 25, 1118.8 ± 1.9920.1 ± 4.4622.4 ± 4.60
Week 8, n=19, 19, 1019.2 ± 2.3223.4 ± 6.2322.0 ± 1.79
Week 9, n=17, 16, 1219.5 ± 2.9622.0 ± 3.9522.5 ± 4.48
Week 10, n=16, 13, 1118.7 ± 2.2722.8 ± 3.8323.3 ± 6.83
Week 11, n=15, 13, 1218.9 ± 1.2822.8 ± 3.1122.2 ± 5.29
Week 12, n=17, 16, 918.6 ± 1.9022.2 ± 3.7623.6 ± 4.98
Week 13, n=11, 13, 819.3 ± 1.5623.4 ± 7.6821.0 ± 2.62
Week 14, n=13, 11, 718.7 ± 2.9819.9 ± 5.4923.4 ± 4.86
Week 15, n=12, 13, 518.7 ± 1.7621.1 ± 2.5324.4 ± 8.76
Week 16, n=16, 14, 818.6 ± 1.2622.9 ± 7.9724.3 ± 6.88
Week 17, n=13, 10, 519.0 ± 2.0822.4 ± 6.4525.2 ± 9.65
Week 18, n=16, 12, 419.1 ± 3.7922.0 ± 4.5329.0 ± 10.52
Week 19, n=14, 13, 618.1 ± 1.4924.5 ± 19.3324.0 ± 6.45
Week 20, n=13, 13, 717.4 ± 1.9420.9 ± 3.5233.00 ± 16.77
Week 21, n=4, 10, 318.8 ± 3.4020.2 ± 3.5528.0 ± 10.58
Week 22, n=11, 7, 519.7 ± 2.9419.1 ± 2.7926.0 ± 4.90
Week 23, n=8, 7, 620.4 ± 2.7221.1 ± 3.2423.7 ± 5.13
Week 24, n=22, 23, 1119.1 ± 2.0320.2 ± 3.1123.8 ± 5.47
FU Week 1, n=6, 6, 318.8 ± 1.6020.0 ± 3.4126.0 ± 10.39
FU Week 2, n=6, 5, 718.7 ± 1.6320.8 ± 4.1522.2 ± 4.02
FU Week 3, n=6, 4, 419.0 ± 1.6723.0 ± 4.1624.8 ± 5.50
FU Week 4, n=10, 12, 719.4 ± 0.9720.8 ± 1.8621.0 ± 3.74
MPB, n=24, 26, 1523.0 ± 2.7827.7 ± 13.0027.7 ± 11.54
SecondaryMean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1

Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline (MPB) visit included any scheduled and unscheduled post-Baseline assessment..

Time frame:
From Week 1 to Follow-up Week 4 of Part 1, up to Study Week 28
Reported as:
Mean · Beats per minute
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1
Beats per minutePart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
Screening, n=5, 5, 585.2 ± 15.7188.4 ± 8.50102.0 ± 7.97
Day 1, n=4, 5, 5,84.3 ± 11.3288.2 ± 12.89102.4 ± 13.22
Week 1, n= 4, 5, 585.3 ± 4.7990.8 ± 11.19103.8 ± 8.47
Week 2, n=5, 5, 580.4 ± 12.9784.4 ± 16.7796.8 ± 10.66
Week 3, n=5, 5, 592.8 ± 31.1691.4 ± 11.04106.2 ± 11.10
Week 4, n=5, 5, 586.4 ± 10.9284.0 ± 7.6298.6 ± 14.29
Week 5, n=5, 5, 584.6 ± 9.4888.4 ± 9.58107.8 ± 9.58
Week 6, n=5, 5, 476.4 ± 10.5089.8 ± 13.79103.0 ± 8.29
Week 7, n=5, 5, 582.0 ± 9.4696.2 ± 17.84103.2 ± 8.93
Week 8, n=5, 5, 583.0 ± 5.2089.4 ± 15.04111.8 ± 10.62
Week 9, n=5, 5, 580.4 ± 13.3579.2 ± 11.34101.6 ± 5.59
Week 10, n=5, 5, 580.6 ± 14.9384.4 ± 10.31105.4 ± 9.29
Week 11, n=5, 3, 586.6 ± 11.0497.7 ± 16.50106.6 ± 11.19
Week 12, n=4, 4, 580.5 ± 12.0792.0 ± 12.83101.4 ± 16.62
Week 13, n=4, 4, 490.8 ± 15.5286.5 ± 7.05103.8 ± 3.50
Week 14, n=3, 3, 381.0 ± 9.8587.0 ± 8.66101.0 ± 11.00
Week 15, n=3, 4, 477.3 ± 6.6686.8 ± 11.87102.5 ± 3.87
Week 16, n=5, 3, 486.4 ± 18.60103.0 ± 5.5793.0 ± 18.96
Week 17, n=2, 0, 367.5 ± 20.51NA ± NA97.7 ± 12.01
Week 18, n=3, 3, 488.0 ± 10.4486.7 ± 17.01102.8 ± 16.88
Week 19, n=3, 0, 288.0 ± 20.81NA ± NA94.0 ± 8.49
Week 20, n=5, 4, 479.8 ± 13.0396.8 ± 12.58111.8 ± 14.97
Week 21, n=3, 2, 579.0 ± 6.9375.5 ± 3.54101.0 ± 18.63
Week 22, n=3, 4, 470.3 ± 14.3686.5 ± 9.04100.0 ± 18.63
Week 23, n=4, 2, 571.5 ± 13.0382.5 ± 3.54100.0 ± 13.14
Week 24, n=5, 5, 579.6 ± 7.8685.8 ± 6.9196.0 ± 4.74
FU Week 1, n=1, 1, 381.0 ± NA125.0 ± NA107.7 ± 10.79
FU Week 2, n=3, 2, 077.7 ± 8.7484.5 ± 28.99NA ± NA
FU Week 3, n=2, 1, 287.0 ± 2.8378.0 ± NA98.0 ± 8.49
FU Week 4, n=1, 0, 289.0 ± NANA ± NA99.0 ± 26.87
MBP, n=5, 5, 5108.8 ± 24.01109.8 ± 14.17119.6 ± 5.73
SecondaryMean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2

Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment.

Time frame:
From Week 1 to Week 7 of Part 2
Reported as:
Mean · Beats per minute
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2
Beats per minutePart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
Screening, n=8, 16, 9, 1580.1 ± 10.1182.8 ± 17.2886.9 ± 16.1094.3 ± 17.5391.5 ± 6.56101.5 ± 23.48
Day 1, n=6, 14, 9, 1377.2 ± 12.3281.3 ± 8.7093.0 ± 14.0488.8 ± 12.8498.7 ± 5.6999.6 ± 15.84
Week 1, n=8, 16, 9, 1776.4 ± 8.5080.1 ± 12.0489.9 ± 18.4898.4 ± 19.7698.5 ± 13.4496.4 ± 17.08
Week 2, n=7, 15, 9, 1779.4 ± 8.7581.7 ± 9.7989.0 ± 12.4491.8 ± 16.9695.3 ± 7.09102.5 ± 11.81
Week 3, n=8, 16, 9, 1681.5 ± 12.2184.0 ± 10.9386.6 ± 13.3995.8 ± 13.5797.0 ± 14.67102.6 ± 17.44
Week 4, n=8, 16, 9, 1676.3 ± 6.9682.4 ± 10.3984.4 ± 15.9191.5 ± 14.4593.5 ± 17.00116.1 ± 23.26
Week 5, n=8, 16, 9, 1679.3 ± 9.4482.5 ± 13.8795.3 ± 14.9692.4 ± 15.1889.0 ± 15.5299.8 ± 19.51
Week 6, n=8, 16, 9, 1777.0 ± 9.5083.2 ± 11.0186.8 ± 11.6290.1 ± 17.7484.8 ± 13.15103.0 ± 23.14
Week 7, n=8, 16, 9, 1774.1 ± 6.9282.8 ± 11.6896.7 ± 15.3991.6 ± 17.68101.5 ± 16.60105.3 ± 15.18
MBP, n=8, 16, 9, 1788.3 ± 7.7297.6 ± 7.51106.1 ± 11.92108.6 ± 17.08106.8 ± 12.28117.5 ± 21.68
SecondaryMean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3

Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Time frame:
From Week 1to Follow-up Week 4 of Part 2/3, up to Study Week 35
Reported as:
Mean · Beats per minute
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3
Beats per minutePart 2/3 (Eltrombopag Period) Cohort 1Part 2/3 (Eltrombopag Period) Cohort 2Part 2/3 (Eltrombopag Period) Cohort 3
Screening, n=16, 15, 1082.8 ± 17.2894.3 ± 17.53104.8 ± 21.82
Day 1 , n=22, 22, 1578.7 ± 8.6792.0 ± 14.14100.8 ± 15.71
Week 1, n=24, 26, 1479.9 ± 10.8294.8 ± 17.5497.8 ± 15.67
Week 2, n=23, 26, 1379.9 ± 10.0292.5 ± 16.9199.8 ± 12.64
Week 3, n=24, 24, 1283.3 ± 10.6395.4 ± 12.3199.4 ± 16.56
Week 4, n=24, 25, 1381.9 ± 9.8191.7 ± 13.42110.6 ± 22.55
Week 5, n=24, 24, 1180.8 ± 13.0091.7 ± 14.7297.4 ± 17.92
Week 6, n=23, 24, 1182.2 ± 10.4591.6 ± 16.82102.8 ± 20.31
Week 7, n=22, 25, 1182.1 ± 11.4791.1 ± 16.61101.5 ± 16.91
Week 8, n=19, 20, 1079.9 ± 11.8590.8 ± 16.6894.2 ± 25.71
Week 9, n=17, 16, 1287.4 ± 15.7591.9 ± 17.79100.9 ± 15.19
Week 10, n=16, 13, 1187.9 ± 11.7494.3 ± 17.8297.8 ± 18.77
Week 11, n=15, 14, 1281.5 ± 10.2089.3 ± 16.2899.3 ± 15.39
Week 12, n=17, 16, 981.1 ± 11.9891.1 ± 16.39105.3 ± 19.58
Week 13, n=11, 13, 878.1 ± 8.4797.0 ± 21.7999.5 ± 20.57
Week 14, n=13, 12, 774.5 ± 11.1594.8 ± 18.0795.6 ± 12.09
Week 15, n=12, 14, 582.5 ± 9.4194.4 ± 18.9498.0 ± 8.72
Week 16, n=17, 14, 8v81.3 ± 11.2491.4 ± 15.0899.8 ± 17.16
Week 17, n=13, 11, 579.7 ± 11.6996.1 ± 20.80102.2 ± 22.61
Week 18, n=16, 12, 481.1 ± 8.7995.8 ± 23.0199.8 ± 5.56
Week 19, n=14, 14, 682.1 ± 12.3396.5 ± 20.24104.2 ± 18.88
Week 20, n=13, 13, 779.0 ± 10.9895.9 ± 17.4491.6 ± 17.18
Week 21, n=4, 10, 382.3 ± 10.5390.3 ± 10.7199.7 ± 15.28
Week 22, n=11, 6, 583.2 ± 10.5799.7 ± 5.5098.6 ± 18.20
Week 23, n=8, 7, 680.4 ± 11.2589.0 ± 22.3896.2 ± 10.68
Week 24, n=23, 23, 1181.2 ± 9.7093.5 ± 12.5995.3 ± 17.75
FU Week 1, n=6, 6, 386.3 ± 5.8594.2 ± 18.03100.0 ± 20.07
FU Week 2, n=8, 7, 783.0 ± 8.5487.9 ± 12.77110.0 ± 27.47
FU Week 3, n=6, 5, 483.7 ± 13.0392.4 ± 11.5592.0 ± 12.19
FU Week 4, n=11, 13, 781.6 ± 11.8992.3 ± 16.10102.3 ± 18.87
MPB, n=24, 26, 15102.2 ± 9.35110.9 ± 15.03121.2 ± 20.42
SecondaryNumber of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1

Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.

Time frame:
Baseline and Week 24 of Part 1
Reported as:
Number · Participants
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1
ParticipantsPart 1 Eltrombopag Dose-Finding Period
UP, MS, BL, n=31
UP, NR, BL, n=30
UP, Neg, BL, n=30
UP, Trace, BL, n=32
UP, 1+, BL, n=30
UP, 2+, BL, n=30
UP, 3+, BL, n=30
UP, 4+, BL, n=30
UG, MS, BL, n=30
UG, NR, BL, n=30
UG, Neg, BL, n=33
UG, normal, BL, n=30
UG, 5, BL, n=30
UG, 15(1+), BL, n=30
UG, 30(2+), BL, n=30
UG, 60(3+), BL, n=30
UG, 110(4+), BL, n=30
UK, MS, BL, n=30
UK, NR, BL, n=30
UK, Neg, BL, n=33
UK, Trace(5), BL, n=30
UK, Small(15), BL, n=30
UK, Moderate(40), BL, n=30
UK, Large(80), BL, n=30
UK, Large(160), BL, n=30
UOB, MS, BL,n=31
UOB, NR, BL,n=30
UOB, Neg, BL,n=32
UOB, 1+, BL,n=30
UOB, 2+, BL,n=30
UOB, 3+, BL,n=30
UOB, Non haemolysed trace, BL,n=30
UOB, haemolysed trace, BL,n=30
pH, MS, BL, n=30
pH, NR, BL, n=30
pH, normal result, BL, n=30
pH, Neg, BL, n=30
pH, 5, BL, n=30
pH, 5.5, BL, n=30
pH, 6, BL, n=30
pH, 6.5, BL, n=31
pH, 7, BL, n=30
pH, 7.5,BL, n=31
pH, 8, BL, n=31
pH, 8.5, BL, n=30
pH, 9, BL, n=30
UP, MS, W24, n=40
UP, NR, W24, n=40
UP, Neg, W24, n=43
UP, Trace, W24, n=41
UP, 1+, W24, n=40
UP, 2+, W24, n=40
UP, 3+, W24, n=40
UP, 4+, W24, n=40
UG, MS, W24, n=40
UG, NR, W24, n=40
UG, Neg, W24, n=44
UG, normal, W24, n=40
UG, 5, W24, n=40
UG, 15(1+), W24, n=40
UG, 30(2+), W24, n=40
UG, 60(3+), W24, n=40
UG, 110(4+), W24, n=40
UK, MS, W24, n=40
UK, NR, W24, n=40
UK, Neg, W24, n=43
UK, Trace(5), W24, n=41
UK, Small(15), W24, n=40
UK, Moderate(40), W24, n=40
UK, Large(80), W24, n=40
UK, Large(160), W24, n=40
UOB, MS, W24, n=40
UOB, NR, W24, n=40
UOB, Neg, W24, n=43
UOB, 1+, W24, n=40
UOB, 2+, W24, n=40
UOB, 3+, W24, n=40
UOB, Non haemolysed trace, W24, n=40
UOB, haemolysed trace, W24, n=40
pH, MS, W24, n=40
pH, NR, W24, n=40
pH, normal result, W24, n=40
pH, Neg, W24, n=40
pH, 5, W24, n=40
pH, 5.5, W24, n=40
pH, 6, W24, n=42
pH, 6.5, W24, n=42
pH, 7, W24, n=40
pH, 7.5,W24, n=40
pH, 8, W24, n=40
pH, 8.5, W24, n=40
pH, 9, W24, n=40
SecondaryNumber of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2

Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 7 (W7). The Baseline value was the measurement taken at Day 1.

Time frame:
Baseline and Week 7 of Part 2
Reported as:
Number · Participants
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2
ParticipantsPart 2 Randomized Period - PlaceboPart 2 Randomized Period - Eltrombopag
UP, MS, BL, n=10, 920
UP, NR, BL, n=10, 901
UP, Neg, BL, n=10, 978
UP, Trace, BL, n=10, 910
UP, 1+, BL, n=10, 900
UP, 2+, BL, n=10, 900
UP, 3+, BL, n=10, 900
UP, 4+, BL, n=10, 900
UG, MS, BL, n=10, 920
UG, NR, BL, n=10, 901
UG, Neg, BL, n=10, 968
UG, normal, BL, n=10, 920
UG, 5, BL, n=10, 900
UG, 15(1+), BL, n=10, 900
UG, 30(2+), BL, n=10, 900
UG, 60(3+), BL, n=10, 900
UG, 110(4+), BL, n=10, 900
UK, MS, BL, n=10, 920
UK, NR, BL, n=10, 901
UK, Neg, BL, n=10, 988
UK, Trace(5), BL, n=10, 900
UK, Small(15), BL, n=10, 900
UK, Moderate(40), BL, n=10, 900
UK, Large(80), BL, n=10, 900
UK, Large(160), BL, n=10, 900
UOB, MS, BL, n=9, 921
UOB, NR, BL, n=9, 901
UOB, Neg, BL, n=9, 964
UOB, 1+, BL,n=9, 901
UOB, 2+, BL,n=9, 910
UOB, 3+, BL, n=9, 900
UOB, Non haemolysed trace, BL,n=9, 900
UOB, haemolysed trace, BL, n=9, 900
pH, MS, BL, n=10, 900
pH, NR, BL, n=10, 901
pH, normal result, BL, n=10, 900
pH, Neg, BL, n=10, 900
pH, 5, BL, n=10, 911
pH, 5.5, BL, n=10, 911
pH, 6, BL, n=10, 934
pH, 6.5, BL, n=10, 921
pH, 7, BL, n=10, 910
pH, 7.5,BL, n=10, 911
pH, 8, BL, n=10, 910
pH, 8.5, BL, n=10, 900
pH, 9, BL, n=10, 900
UP, MS, W7, n=2, 300
UP, NR, W7, n=2, 300
UP, Neg, W7, n=2, 323
UP, Trace, W7, n=2, 300
UP, 1+, W7, n=2, 300
UP, 2+, W7, n=2, 300
UP, 3+, W7, n=2, 300
UP, 4+, W7, n=2, 300
UG, MS, W7, n=2, 300
UG, NR, W7, n=2, 300
UG, Neg, W7, n=2, 323
UG, normal, W7, n=2, 300
UG, 5, W7, n=2, 300
UG, 15(1+), W7, n=2, 300
UG, 30(2+), W7, n=2, 300
UG, 60(3+), W7, n=2, 300
UG, 110(4+), W7, n=2, 300
UK, MS, W7, n=2, 300
UK, NR, W7, n=2, 300
UK, Neg, W7, n=2, 323
UK, Trace(5), W7, n=2, 300
UK, Small(15), W7, n=2, 300
UK, Moderate(40), W7, n=2, 300
UK, Large(80), W7, n=2, 300
UK, Large(160), W7, n=2, 300
UOB, MS, W7, n=2, 310
UOB, NR, W7, n=2, 300
UOB, Neg, W7, n=2, 313
UOB, 1+, W7, n=2, 300
UOB, 2+, W7, n=2, 300
UOB, 3+, W7, n=2, 300
UOB, Non haemolysed trace, W7, n=2, 300
UOB, haemolysed trace, W7, n=2, 300
pH, MS, W7, n=2, 300
pH, NR, W7, n=2, 300
pH, normal result, W7, n=2, 300
pH, Neg, W7, n=2, 300
pH, 5, W7, n=2, 310
pH, 5.5, W7, n=2, 300
pH, 6, W7, n=2, 301
pH, 6.5, W7, n=2, 301
pH, 7, W7, n=2, 311
pH, 7.5, W7, n=2, 300
pH, 8, W7, n=2, 300
pH, 8.5, W7, n=2, 300
pH, 9, W7, n=2, 300
SecondaryNumber of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3

Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.

Time frame:
Baseline and Week 24 of Part 2/3 up to Study Week 31
Reported as:
Number · Participants
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3
ParticipantsPart 2/ 3 Eltrombopag Open-Label Period
UP, MS, BL, n=110
UP, NR, BL, n=111
UP, Neg, BL, n=1110
UP, Trace, BL, n=110
UP, 1+, BL, n=110
UP, 2+, BL, n=110
UP, 3+, BL, n=110
UP, 4+, BL, n=110
UG, MS, BL, n=110
UG, NR, BL, n=111
UG, Neg, BL, n=1110
UG, normal, BL, n=110
UG, 5, BL, n=110
UG, 15(1+), BL, n=110
UG, 30(2+), BL, n=110
UG, 60(3+), BL, n=110
UG, 110(4+), BL, n=110
UK, MS, BL, n=110
UK, NR, BL, n=111
UK, Neg, BL, n=1110
UK, Trace(5), BL, n=110
UK, Small(15), BL, n=110
UK, Moderate(40), BL, n=110
UK, Large(80), BL, n=110
UK, Large(160), BL, n=110
UOB, MS, BL,n=112
UOB, NR, BL,n=111
UOB, Neg, BL,n=115
UOB, 1+, BL,n=111
UOB, 2+, BL,n=110
UOB, 3+, BL,n=110
UOB, Non haemolysed trace, BL,n=110
UOB, haemolysed trace, BL,n=110
pH, MS, BL, n=110
pH, NR, BL, n=111
pH, normal result, BL, n=110
pH, Neg, BL, n=110
pH, 5, BL, n=112
pH, 5.5, BL, n=111
pH, 6, BL, n=114
pH, 6.5, BL, n=111
pH, 7, BL, n=111
pH, 7.5,BL, n=111
pH, 8, BL, n=110
pH, 8.5, BL, n=110
pH, 9, BL, n=110
UP, MS, W24, n=342
UP, NR, W24, n=340
UP, Neg, W24, n=3432
UP, Trace, W24, n=340
UP, 1+, W24, n=340
UP, 2+, W24, n=340
UP, 3+, W24, n=340
UP, 4+, W24, n=340
UG, MS, W24, n=41
UG, NR, W24, n=40
UG, Neg, W24, n=3329
UG, normal, W24, n=333
UG, 5, W24, n=330
UG, 15(1+), W24, n=330
UG, 30(2+), W24, n=330
UG, 60(3+), W24, n=330
UG, 110(4+), W24, n=330
UK, MS, W24, n=331
UK, NR, W24, n=330
UK, Neg, W24, n=3332
UK, Trace(5), W24, n=330
UK, Small(15), W24, n=330
UK, Moderate(40), W24, n=330
UK, Large(80), W24, n=330
UK, Large(160), W24, n=330
UOB, MS, W24, n=331
UOB, NR, W24, n=330
UOB, Neg, W24, n=3331
UOB, 1+, W24, n=330
UOB, 2+, W24, n=330
UOB, 3+, W24, n=330
UOB, Non haemolysed trace, W24, n=330
UOB, haemolysed trace, W24, n=330
pH, MS, W24, n=340
pH, NR, W24, n=340
pH, normal result, W24, n=340
pH, Neg, W24, n=340
pH, 5, W24, n=340
pH, 5.5, W24, n=344
pH, 6, W24, n=3410
pH, 6.5, W24, n=344
pH, 7, W24, n=3411
pH, 7.5,W24, n=343
pH, 8, W24, n=342
pH, 8.5, W24, n=340
pH, 9, W24, n=340
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

Time frame:
From Treatment + 1 day up to Week 24 of Part1
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1
ParticipantsPart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
Any AE555
Any SAE110
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

Time frame:
From Treatment + 1 day up to Week 7 of Part 2
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2
ParticipantsPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- Eltrombopag
Any AE81391439
Any SAE111300
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2/3

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

Time frame:
From Treatment + 1 day up to Week 31 of Part2/3
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2/3
ParticipantsPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open- Label Period) Cohort 3
Any AE222614
Any SAE350
SecondaryNumber of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with a change in visual acuity and worsening visual acuity due to cataracts since Baseline are presented for Part 1 Follow-up Visits at 3-months (FU3) and at 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".

Time frame:
Baseline, 3and 6-mo Follow-up of Part 1
Reported as:
Number · Participants
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1
ParticipantsPart 1 (Dose-Finding Period) Cohort 1Part 1 (Dose-Finding Period) Cohort 2Part 1 (Dose-Finding Period) Cohort 3
Change in VA at FU3, no112
Change in VA at FU3, yes001
Change in VA at FU6, no445
Change in VA at FU6, yes000
Change due to cataracts at FU3, no001
Change due to cataracts at FU3, yes000
Change due to cataracts at FU6, no000
Change due to cataracts at FU6, yes000
SecondaryNumber of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Number of participants with a change in visual acuity and change in visual acuity due to the worsening of cataracts since Baseline are presented for Part 2/3 Follow-up Visits at 3-months (FU3) and 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".

Time frame:
BL, 3 and 6mo Follow-up of Part 2/3
Reported as:
Number · Participants
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts
ParticipantsPart 2/3 (Eltrombopag Open-Label Period) Cohort 1Part 2/3 (Eltrombopag Open-Label Period) Cohort 2Part 2/3 (Eltrombopag Open- Label Period) Cohort 3
Change in VA at FU3, no13179
Change in VA at FU3, yes412
Change in VA at FU6, no16226
Change in VA at FU6, yes423
Change due to cataracts at FU3, no412
Change due to cataracts at FU3, yes000
Change due to cataracts at FU6, no423
Change due to cataracts at FU6, yes000

Adverse events

Collected over On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 (Dose-Finding Period)—2/15 (13.3%)15/15 (100%)
Part 2 (Randomized Period) -Placebo—2/21 (9.5%)20/21 (95.2%)
Part 2 (Randomized Period) - Eltrombopag—4/44 (9.1%)36/44 (81.8%)
Part 2/ 3 (Eltrombopag Open-Label Period)—8/65 (12.3%)62/65 (95.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPart 1 (Dose-Finding Period)Part 2 (Randomized Period) -PlaceboPart 2 (Randomized Period) - EltrombopagPart 2/ 3 (Eltrombopag Open-Label Period)
NeutropeniaBlood and lymphatic system disorders1/150/211/441/65
EpistaxisRespiratory, thoracic and mediastinal disorders1/151/210/441/65
ImpetigoInfections and infestations0/151/210/440/65
VaricellaInfections and infestations0/151/210/440/65
ConjunctivitisEye disorders0/151/210/440/65
AnaemiaBlood and lymphatic system disorders0/150/211/441/65
Febrile neutropeniaBlood and lymphatic system disorders0/150/211/441/65
PyrexiaGeneral disorders0/150/211/441/65
Urinary tract infectionInfections and infestations0/150/211/441/65
Lenticular opacitiesEye disorders0/150/210/441/65
Most frequent other events
Showing 10 of 194
Most frequent other events
EventPart 1 (Dose-Finding Period)Part 2 (Randomized Period) -PlaceboPart 2 (Randomized Period) - EltrombopagPart 2/ 3 (Eltrombopag Open-Label Period)
HeadacheNervous system disorders8/159/2113/4428/65
VomitingGastrointestinal disorders6/156/214/4410/65
Upper respiratory tract infectionInfections and infestations5/152/2111/4424/65
DiarrhoeaGastrointestinal disorders5/151/217/4417/65
NauseaGastrointestinal disorders1/156/216/4415/65
Abdominal painGastrointestinal disorders2/152/213/4415/65
PyrexiaGeneral disorders0/153/216/4415/65
EpistaxisRespiratory, thoracic and mediastinal disorders3/153/211/4411/65
CoughRespiratory, thoracic and mediastinal disorders1/150/213/449/65
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/151/215/449/65

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1 Eltrombopag Dose-Finding PeriodPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- EltrombopagTotal
Mean9.1 ± 4.6114.6 ± 1.6913.7 ± 1.588.6 ± 2.248.2 ± 1.873.6 ± 1.343.3 ± 1.349.3 ± 4.49
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Eltrombopag Dose-Finding PeriodPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- EltrombopagTotal
Female8388142548
Male758153534
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 Eltrombopag Dose-Finding PeriodPart 2 (Randomized Period) Cohort 1-PlaceboPart 2 (Randomized Period) Cohort 1- EltrombopagPart 2 (Randomized Period) Cohort 2-PlaceboPart 2 (Randomized Period) Cohort 2-EltrombopagPart 2 (Randomized Period) Cohort 3-PlaceboPart 2 (Randomized Period) Cohort 3- EltrombopagTotal
African American/African Heritage20001003
Asian - Japanese/East Asian Heritage21011016
White - White/Caucasian/European97148175767
Unknown10000001
White - Arabic/North African Heritage00100012
Mixed Race10100013
09

Study locations

33 sites
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Jacksonville, Florida 32207, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Orlando, Florida 32827, United States
  • GSK Investigational Site
    Chicago, Illinois 60611-2605, United States
  • GSK Investigational Site
    Peoria, Illinois 61614, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87106, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28203, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • GSK Investigational Site
    Memphis, Tennessee 38105, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Seattle, Washington 98105, United States
  • GSK Investigational Site
    Toronto, Ontario M5G 1X8, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1C5, Canada
  • GSK Investigational Site
    Bordeaux cedex, 33076, France
  • GSK Investigational Site
    Paris cedex 12, 75571, France
  • GSK Investigational Site
    Paris Cedex 19, 75935, France
  • GSK Investigational Site
    Rotterdam, 3015 GJ, Netherlands
  • GSK Investigational Site
    Barakaldo (Vizcaya), 48903, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28009, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Cardiff, CF14 4XW, United Kingdom
  • GSK Investigational Site
    London, W2 1NY, United Kingdom
  • GSK Investigational Site
    Manchester, M13 9WL, United Kingdom
  • GSK Investigational Site
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • GSK Investigational Site
    Southampton, SO16 6YD, United Kingdom
10

References and documents

Publications

  • Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Br J Haematol. 2019 Apr;185(1):102-106. doi: 10.1111/bjh.15732. Epub 2018 Dec 27. PubMed 30592022 ↗
  • Wire MB, Li X, Zhang J, Sallas W, Aslanis V, Ouatas T. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia. Clin Pharmacol Ther. 2018 Dec;104(6):1199-1207. doi: 10.1002/cpt.1066. Epub 2018 Apr 17. PubMed 29536526 ↗
  • Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28. Erratum In: Lancet Haematol. 2015 Oct;2(10):e407. PubMed 26688484 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2009
First posted
May 25, 2009
Start
Sep 30, 2009
Primary completionActual
Feb 1, 2014
CompletionActual
Feb 1, 2014
Results first posted
Oct 31, 2014
Last update
Oct 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00908037
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 25, 2009
Start date
Sep 30, 2009
Primary completion
Feb 1, 2014
Completion
Feb 1, 2014
Results posted
Oct 31, 2014
Last update
Oct 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion